Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C, Kilgour E, Smith NR, Geh C, Rooney C, Cutts R, Campbell J, Ning J, Fenwick K, Swain A, Brown G, Chua S, Thomas A, Johnston SRD, Ajaz M, Sumpter K, Gillbanks A, Watkins D, Chau I, Popat S, Cunningham D, Turner NC.

Cancer Discov. 2016 Aug;6(8):838-851. doi: 10.1158/2159-8290.CD-15-1246. Epub 2016 May 13.

2.

Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon.

Rooney C, Geh C, Williams V, Heuckmann JM, Menon R, Schneider P, Al-Kadhimi K, Dymond M, Smith NR, Baker D, French T, Smith PD, Harrington EA, Barrett JC, Kilgour E.

PLoS One. 2016 Feb 23;11(2):e0149628. doi: 10.1371/journal.pone.0149628. eCollection 2016.

3.

Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples.

Veldman-Jones MH, Brant R, Rooney C, Geh C, Emery H, Harbron CG, Wappett M, Sharpe A, Dymond M, Barrett JC, Harrington EA, Marshall G.

Cancer Res. 2015 Jul 1;75(13):2587-93. doi: 10.1158/0008-5472.CAN-15-0262. Epub 2015 Jun 11. Review.

4.

Assessed and distressed: white-coat effects on clinical balance performance.

Geh CL, Beauchamp MR, Crocker PR, Carpenter MG.

J Psychosom Res. 2011 Jan;70(1):45-51. doi: 10.1016/j.jpsychores.2010.09.008.

PMID:
21193100
5.

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.

Byth KF, Thomas A, Hughes G, Forder C, McGregor A, Geh C, Oakes S, Green C, Walker M, Newcombe N, Green S, Growcott J, Barker A, Wilkinson RW.

Mol Cancer Ther. 2009 Jul;8(7):1856-66. doi: 10.1158/1535-7163.MCT-08-0836. Epub 2009 Jun 9.

6.

The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing.

Jones CD, Andrews DM, Barker AJ, Blades K, Daunt P, East S, Geh C, Graham MA, Johnson KM, Loddick SA, McFarland HM, McGregor A, Moss L, Rudge DA, Simpson PB, Swain ML, Tam KY, Tucker JA, Walker M.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6369-73. doi: 10.1016/j.bmcl.2008.10.102. Epub 2008 Oct 25.

PMID:
18996007
7.

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.

Jones CD, Andrews DM, Barker AJ, Blades K, Byth KF, Finlay MR, Geh C, Green CP, Johannsen M, Walker M, Weir HM.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9. doi: 10.1016/j.bmcl.2008.10.075. Epub 2008 Oct 22.

PMID:
18986805
8.

The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor.

Byth KF, Geh C, Forder CL, Oakes SE, Thomas AP.

Mol Cancer Ther. 2006 Mar;5(3):655-64.

Supplemental Content

Support Center